LissoniP., BarniS., RovelliF., VivianeS., MaestroniG.J., ContiA., TanciniG.The biological significance of soluble interleukin-2 receptors in solid tumors.Eur J Cancer1990; 26: 33–6.
5.
RubinL.A., KurmanC.C., FritzM.E.. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro.J Immunol1985; 135: 3172–7.
6.
BartonD.P.J., BlanchardD.K., WellsA.F., NicosiaS.V., RobertsW.S., CavanaghD., DjeuJ.Y.Expression of interleukin-2 receptor alpha (sIL-2α) mRNA and protein in advanced epithelial ovarian cancer.Anticancer Res1994; 14: 761–72.
7.
GoodingR., RichesP., DadianG., MooreJ., GoreM.Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.Br J Cancer1995; 72: 452–5.
8.
Fernandez-BotranR.Soluble cytokine receptors: their role in immunoregulation.FASEB J1991; 5: 2567–74.
HurteauJ.A., SimonH.U., KurmanC., RubinL., MillsG.B.Levels of soluble interleukin-2 receptor α are elevated in serum and ascitic fluid from epithelial ovarian cancer patients.Am J Obstet Gynecol1994; 170: 918–28.
11.
BartonD.P.J., BlanchardD.K.High serum and ascites soluble interleukin-2 receptor α levels in advanced epithelial ovarian cancer.Blood1993; 81: 424–9.
PavlidisN.A., BairkatariE., Kalef-EzraJ., NicolaidesC., SeferiadisC., FountzilasG.Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.Int J Biol Markers1995; 10: 75–80.
14.
GebauerG., RiegerM., JaegerW., LangN.Serum concentrations of soluble interleukin-2 receptors (sIL-2R) in patients with benign and malignant ovarian tumors.Eur J Cancer1997; 33(Suppl 8): 122.
15.
GebauerG., RiegerM., JaegerW., LangN.Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.Anticancer Res1998; in press.
16.
BuccheriG., MarinoP., PreatoniA., FerrignoD., MoroniG.A.Soluble interleukin 2 receptor in lung cancer.An indirect marker of tumor activity? Chest1991; 99: 1433–7.
